<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03553303</url>
  </required_header>
  <id_info>
    <org_study_id>3403003</org_study_id>
    <nct_id>NCT03553303</nct_id>
  </id_info>
  <brief_title>Pharmacodynamic Effects of Sacubitril/Valsartan on Natriuretic Peptides, Angiotensin and Neprilysin</brief_title>
  <official_title>Pharmacodynamic Effects of Sacubitril/Valsartan on Natriuretic Peptides, Angiotensin and Neprilysin. A Ringerike Heart Failure Cohort Phase IV Study of Angiotensin Receptor Neprilysin Inhibiton</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study measure multiple neurohormones in patients with heart failure being treated with
      Sacubitril/Valsartan in increasing doses over an 8 week period.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 16, 2018</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neurohormonal plasma concentration</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Heart Failure, Systolic</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Increasing doses of Sacubitril/Valsartan</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sacubitril / Valsartan Oral Tablet</intervention_name>
    <description>Increasing doses of Sacubitril/Valsartan</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients must give written informed consent before any study assessment is performed.

          2. Ambulatory ≥ 18 years of age, male or female, treated at Ringerike Hospital.

          3. Patients with symptomatic chronic heart failure and reduced ejection fraction (≤ 40%).

          4. Patients on optimized medical treatment for heart failure. -

        Exclusion Criteria:

          1. Patients not able to comply in the study.

          2. Patients having contraindication for treatment with Entresto;

               1. Hypersensitivity to the active substances or to any of the excipients listed in
                  section

               2. Hyperkalemia: &gt; 5.4 mmol/L

               3. Known history of angioedema related to previous ACE inhibitor or ARB therapy.

               4. Hereditary or idiopathic angioedema.

               5. Concomitant use with Aliskiren-containing medicinal products in patients with
                  diabetes mellitus or in patients with renal impairment (eGFR &lt;60 ml/min/1.73m2)

               6. End-stage renal disease (&lt;15 mL/min per 1.73m2 or treatment by dialysis).

               7. Severe hepatic impairment, biliary cirrhosis and cholestasis (Child-Pugh C
                  classification).

               8. Pregnancy Breast-feeding-
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Hall, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Oslo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christian Hall, MD PhD</last_name>
    <phone>+4747500900</phone>
    <email>chall@medisin.uio.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ingeborg Haugli, MD</last_name>
    <phone>+4791887090‬</phone>
    <email>ingeborg.haugli@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ringerike Hospital Vestre Viken Hospital Trust</name>
      <address>
        <city>Hønefoss</city>
        <state>Buskerud</state>
        <zip>3511</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Hall</last_name>
      <phone>+4747500900</phone>
    </contact>
    <contact_backup>
      <last_name>Hall</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>May 23, 2018</study_first_submitted>
  <study_first_submitted_qc>June 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 12, 2018</study_first_posted>
  <last_update_submitted>August 28, 2019</last_update_submitted>
  <last_update_submitted_qc>August 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Christian Hall</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Heart Failure, Systolic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valsartan</mesh_term>
    <mesh_term>LCZ 696</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

